Takeda Pharmaceutical Company Limited

Total Valuation

Takeda Pharmaceutical Company Limited carries a market capitalization of 56.83B, placing it among publicly traded companies globally. Its enterprise value stands at 8.53T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Takeda Pharmaceutical Company Limited currently has 1.58B shares outstanding.

Valuation Ratios

Takeda Pharmaceutical Company Limited trades at a trailing price-to-earnings ratio of 68.15. The price-to-sales ratio is 1.78, and the price-to-book ratio stands at 0.55.

Enterprise Valuation

On an enterprise value basis, Takeda Pharmaceutical Company Limited trades at an EV/EBITDA multiple of 8.36 and an EV/FCF ratio of 6.58. The EV/Sales ratio of 1.85 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.73 provides insight into valuation relative to core operating earnings.

Financial Position

Takeda Pharmaceutical Company Limited maintains a current ratio of 1.14, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 65.35, indicating elevated leverage, while an interest coverage ratio of 9.74 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Takeda Pharmaceutical Company Limited has paid 32.88B in income taxes, reflecting an effective tax rate of 194.54.

Stock Price Statistics

Takeda Pharmaceutical Company Limited's stock has gained approximately 22.32877% over the past 52 weeks. The 50-day moving average sits at 18.01, while the 200-day moving average is 17.15.

Income Statement

Over the trailing twelve months, Takeda Pharmaceutical Company Limited generated 4.62T in revenue and converted that into -163.44B in net income, yielding earnings per share of -50.83. EBITDA reached 1.02T, while operating income came in at 481.30B.

Balance Sheet

Takeda Pharmaceutical Company Limited holds 527.58B in cash and equivalents against 4.94T in total debt, resulting in a net debt position of 4.48T. Total book value stands at 7.56T, with working capital of 385.72B providing operational flexibility.

Cash Flow

Takeda Pharmaceutical Company Limited produced 826.14B in operating cash flow over the past twelve months. After subtracting -339.59B in capital expenditures, free cash flow totaled 486.54B - equivalent to 153.98 per share.

Margins

Takeda Pharmaceutical Company Limited operates with a gross margin of 65.50, reflecting its pricing power and cost economics. The operating margin of 10.42 and net profit margin of -3.54 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -102.30 indicates the proportion of earnings distributed to shareholders.

Scores

Takeda Pharmaceutical Company Limited posts an Altman Z-Score of 1.50, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.